These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1423243)

  • 21. Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview.
    Rosen HR
    Neoplasma; 1996; 43(6):357-62. PubMed ID: 8996558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis.
    Schöndorf T; Göhring UJ; Becker M; Hoopmann M; Schmidt T; Rützel S; Rein DT; Ulrich U; Fechteler R; Bersch A; Mallmann P; Valter MM
    Pathobiology; 2004; 71(4):217-22. PubMed ID: 15263811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes.
    Garty B; Kaminsky E; Moroz C
    Clin Diagn Lab Immunol; 1995 Mar; 2(2):225-6. PubMed ID: 7697533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
    Yang DC; Wang F; Elliott RL; Head JF
    Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
    Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
    J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.
    Stierer M; Rosen H; Weber R; Hanak H; Spona J; Tüchler H
    Ann Surg; 1993 Jul; 218(1):13-21. PubMed ID: 8328824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of prognostic parameters in patients with breast cancer of size smaller than or equal to 2 cm].
    Xue C; Fu F; Wang C
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):245-9. PubMed ID: 25975906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome.
    Nassar A; Lawson D; Cotsonis G; Cohen C
    Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):113-20. PubMed ID: 18227733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
    Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
    Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of plasma placental isoferritin in pathogenesis of preeclampsia and its predictive value for preeclampsia].
    Wang Z; Zhu Y
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):209-11. PubMed ID: 11783362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
    Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
    Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placental isoferritin patterns during first-trimester intrauterine gestation.
    Maymon R; Bar J; Halperin R; Bukovsky I; Moroz C
    Gynecol Obstet Invest; 1996; 42(4):271-3. PubMed ID: 8979102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New monoclonal antibody enzymoassay for the specific measurement of placental ferritin isotype in hematologic malignancies.
    Moroz C; Bessler H; Lurie Y; Shaklai M
    Exp Hematol; 1987 Mar; 15(3):258-62. PubMed ID: 3817052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of syndecan-1 expression in breast cancer.
    Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
    Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
    Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
    Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.